Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD.
Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD.
Pediatr Res. 2018 Jan;83(1-2):223-231. doi: 10.1038/pr.2017.252. Epub 2017 Nov 1.
Recent advances have allowed for three-dimensional (3D) printing technologies to be applied to biocompatible materials, cells and supporting components, creating a field of 3D bioprinting that holds great promise for artificial organ printing and regenerative medicine. At the same time, stem cells, such as human induced pluripotent stem cells, have driven a paradigm shift in tissue regeneration and the modeling of human disease, and represent an unlimited cell source for tissue regeneration and the study of human disease. The ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability. 3D bioprinting has been successfully performed using multiple stem cell types of different lineages and potency. The type of 3D bioprinting employed ranged from microextrusion bioprinting, inkjet bioprinting, laser-assisted bioprinting, to newer technologies such as scaffold-free spheroid-based bioprinting. This review discusses the current advances, applications, limitations and future of 3D bioprinting using stem cells, by organ systems.
近年来,三维(3D)打印技术已经能够应用于生物相容性材料、细胞和支撑组件,从而形成了 3D 生物打印领域,为人工器官打印和再生医学带来了巨大的前景。与此同时,干细胞,如人类诱导多能干细胞,推动了组织再生和人类疾病建模的范式转变,为组织再生和人类疾病研究提供了无限的细胞来源。对患者特异性细胞进行重编程的能力有望增强对疾病机制和表型变异性的理解。已经成功地使用不同谱系和潜能的多种干细胞类型进行了 3D 生物打印。所采用的 3D 生物打印技术包括微挤出生物打印、喷墨生物打印、激光辅助生物打印,以及新型技术,如无支架球体基生物打印。本文按器官系统讨论了当前使用干细胞的 3D 生物打印的进展、应用、局限性和未来。